翻译后剪接修饰作为急性髓系白血病阿糖胞苷耐药的关键机制
尽管已有多种药物获批,阿糖胞苷仍广泛用于急性髓系白血病(AML)治疗,但85%患者出现耐药,仅10%克服疾病。研究通过RNA测序和磷酸化蛋白质组学发现,耐药过程中RNA剪接及富含丝氨酸-精氨酸(SR)蛋白磷酸化发生改变,诊断时应答者的SR蛋白磷酸化显著低于无应答者。剪接抑制剂单用或联合其他获批药物对敏感和耐药AML细胞均有效,H3B-8800与维奈克拉联合在体外显示最佳疗效,在患者样本中表现协同效应,对健康造血祖细胞无毒性。
要点
- AML中85%患者对阿糖胞苷耐药,仅10%克服疾病。
- 诊断时应答者SR蛋白磷酸化显著低于无应答者,或可预测疗效。
- H3B-8800联合维奈克拉在体外对敏感和耐药AML细胞显示协同效应。
核心结论
- RNA剪接抑制单用或联合维奈克拉可能有助于治疗新诊断或复发/难治性AML。
研究设计与样本
- 研究采用RNA测序和磷酸化蛋白质组学分析阿糖胞苷耐药过程中的RNA剪接和SR蛋白磷酸化改变。
主要发现
- 阿糖胞苷耐药过程中RNA剪接和SR蛋白磷酸化发生改变。
- 诊断时应答者的SR蛋白磷酸化显著低于无应答者。
- SR蛋白靶基因的转录组谱发生改变。
- 剪接抑制剂单用或联合其他获批药物对敏感和耐药AML细胞均有效。
- H3B-8800与维奈克拉联合在体外对患者样本显示协同效应,对健康造血祖细胞无毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the approval of several drugs for AML, cytarabine is still widely used as a therapeutic approach. However, 85% of patients show resistance and only 10% overcome the disease. Using RNA-seq and phosphoproteomics, we show that RNA splicing and serine-arginine-rich (SR) proteins phosphorylation were altered during cytarabine resistance. Moreover, phosphorylation of SR proteins at diagnosis were significantly lower in responder than non-responder patients, pointing to their utility to predict response. These changes correlated with altered transcriptomic profiles of SR protein target genes. Notably, splicing inhibitors were therapeutically effective in treating sensitive and resistant AML cells as monotherapy or combination with other approved drugs. H3B-8800 and venetoclax combination showed the best efficacy in vitro, demonstrating synergistic effects in patient samples and no toxicity in healthy hematopoietic progenitors. Our results establish that RNA splicing inhibition, alone or combined with venetoclax, could be useful for the treatment of newly diagnosed or relapsed/refractory AML.
引用
- Morales ML, García-Vicente R, Rodríguez-García A, et al. Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia. Leukemia. 2023. PMID: 37422594. doi:10.1038/s41375-023-01963-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。